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Endothelial progenitor cells (EPCs) are hematopoietic 
cells derived from immature bone marrow that circulate 
in the peripheral blood [1]. EPCs have the capability to 
diﬀ  erentiate into mature endothelial cells and are assumed 
to replace dysfunctional endothelium. Consistent with 
this hypothesis, decreased levels of EPCs were shown to 
predict atherosclerotic disease progression and to be an 
independent risk factor for cardiovascular events [2]. 
After ischemic stroke, EPC levels decrease [3]. On the 
other hand, increasing EPC numbers during the acute 
phase of stroke are associated with smaller lesion growth 
and with improved neurological outcome [3,4]. Th  ere-
fore, pharmacological mobilization of EPCs from the 
bone marrow may enhance functional recovery post-
stroke. A potential candidate stroke drug that increases 
the number of circulating EPCs is erythropoietin (EPO) 
[5]. Several preclinical stroke studies demonstrated the 
eﬃ   cacy of EPO in reducing infarct volumes and in improv-
ing recovery of neurological function [6]. However, no 
human stroke study so far investigated the eﬀ  ects of EPO 
on both neurological outcome and EPC levels.
In the previous issue of Critical Care, Yip and colleagues 
[1] report on a prospective clinical trial in which 167 
ischemic stroke patients were randomized to receive either 
5,000 IU EPO or placebo subcutaneously at 48 and 
72 hours after symptom onset. On day 21, EPC levels were 
signiﬁ  cantly higher in the EPO group. After 90 days, EPO 
treatment was associated with a signiﬁ    cantly  lower 
proportion of patients with a National Institute of Health 
Stroke Scale (NIHSS) score ≥8 as well as with signiﬁ  cant 
reductions in recurrent strokes and in the composite end-
point of recurrent stroke, NIHSS ≥8 and death. Overall, 
two questions arise: is bone marrow stimulation to increase 
EPC levels in the peripheral blood a suitable therapy for 
stroke; and is EPO a candidate drug that can improve 
neurological outcome post-stroke by EPC stimulation?
Since increasing EPC levels post-stroke were shown to 
be associated with a favorable outcome, the primary 
question is whether EPCs are only a surrogate marker of 
neurological improvement or whether a causal relation-
ship exists. Actually, both possibilities are reasonable. 
EPC numbers were shown to be lower in stroke patients 
with more severe neurological deﬁ  cits who, in turn, have 
a reduced potential for recovery compared to patients 
with less severe deﬁ   cits and higher EPC levels [7]. A 
pathophysiological explanation for the hypothesis that 
EPCs reﬂ  ect only the severity of stroke is the assumption 
that larger infarcts cause an excessive consumption of 
EPCs for endothelial repair, with subsequent lower peri-
pheral EPC levels [8]. However, results of experimental 
stroke studies suggest a causal association between EPCs 
and improved functional recovery because EPC adminis-
tration leads to reduced infarct volumes and improved 
functional recovery in diﬀ   erent animal stroke models 
[9-11]. Increased EPC-derived angiogenesis in the peri-
infarct region was identiﬁ  ed as an underlying mechanism.
So, is EPO a suitable drug for EPC stimulation in stroke 
patients? Besides other mechanisms in stroke, such as 
anti-apoptotic eﬀ  ects and increasing neurogenesis and 
angiogenesis, EPO was found to enhance EPC numbers 
[5,12]. However, in contrast to pathophysiological con-
sidera  tions and results of experimental studies, the 
random  ized phase II/III German Multicenter EPO Stroke 
Trial, which is the largest clinical EPO stroke study that 
has been published so far, was negative [13]. Th  e  primary 
endpoint of the German EPO Trial, change in Barthel 
Index on day 90, and all secondary outcomes, including 
the NIHSS and the modiﬁ  ed Rankin Scale, failed to show 
any beneﬁ  t of EPO. Moreover, in the German EPO trial 
increased mortality was observed after EPO treatment.
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of Yip and colleagues might be explained by the chosen 
endpoints. Th  e primary endpoint of the present study, 
which was reported at the Current Controlled Trial 
register [14], is the composite of recurrent stroke, NIHSS 
≥8 and death. Th  is endpoint primarily reﬂ  ects the fre-
quency of recurrent stroke on day 90. When considering 
the components of the composite endpoint, the signiﬁ  -
cantly higher number of patients with a NIHSS ≥8 after 
placebo treatment is also likely to be caused by the high 
rate of recurrent strokes and does not necessarily reﬂ  ect 
improved neurological function in the EPO group. 
Concordantly, the means of the NIHSS on day 90 did not 
diﬀ   er between the two groups. Th  e 90-day mortality, 
which is the third component of the composite endpoint, 
was even higher in the EPO group. In contrast to the 
ﬁ  nding of increased mortality after EPO treatment in the 
larger German EPO trial, this diﬀ  erence was statistically 
not signiﬁ  cant.
Overall, the results of the study of Yip and colleagues 
suggest that EPO might be suitable for the secondary 
prevention of ischemic stroke. Th  e  eﬃ   cacy regarding im-
proved neurological outcome, which is usually measured 
by the modiﬁ  ed Rankin Scale or the Barthel Index at day 
90, was not investigated. Moreover, the results of the 
study of Yip and colleagues are weakened by the fact that 
the study was ﬁ  rst assigned to a trial register in January 
2011, which was 10 months after the inclusion of the last 
patients in March 2010 [14]. Th  us, the endpoints were 
not published before completion of the study. Further-
more, there are severe doubts regarding the potency of 
EPO as a drug for secondary stroke prevention, since 
long-term use of EPO was shown to even increase the 
risk for stroke [15].
In conclusion, the potential side eﬀ  ects and the failed 
eﬃ   cacy in a large clinical trial will presumably prevent 
the use of EPO as a therapy to increase EPCs after stroke. 
However, a direct systemic transplantation of EPCs or 
the mobilization of EPCs by other drugs - for example, 
granulocyte colony-stimulating factor - remain as pro-
mis  ing options to improve outcome after stroke [16].
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